Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
Palbociclib and abemaciclib are two cyclin-dependent kinases 4 and 6 used for breast cancer treatment. Levels of these medicines present a significant interindividual variability, so monitoring those concentrations might be necessary in therapy. Most of the methods presented so far in the literature...
Main Authors: | Daniela Maria Calucică, Costel-Valentin Manda, Amelia Maria Găman, Ștefan Răileanu, Liliana Stanca, Monica Denisa Elena Popescu, Olivia Garofița Mateescu, Andrei Biță, Octavian Croitoru, Simona-Daniela Neamțu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/23/8604 |
Similar Items
-
Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01) -
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01) -
Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01) -
Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01) -
Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)